Svensson C K, Ware J A
Department of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, Wayne State University, Detroit, Michigan 48202.
Pharm Res. 1988 Jul;5(7):437-9. doi: 10.1023/a:1015940518439.
Numerous agents that undergo extensive first-pass metabolism have been shown to inhibit oxidative drug metabolism. To examine whether this effect is related to the chemical structure or pharmacokinetic characteristics of the inhibiting agent, we determined the effect of dextromethorphan (a compound which exhibits pharmacokinetic similarities to, but is chemically dissimilar from, previously studied agents) on the disposition of antipyrine. A single oral dose of dextromethorphan hydrobromide, 100 mg/kg, 1 hr prior to antipyrine administration had no significant effect on the pharmacokinetics of this model substrate. The administration of dextromethorphan at the same dose twice daily for 3 days and an additional dose 1 hr prior to antipyrine administration resulted in a 33% increase in the clearance of antipyrine. These data indicate that dextromethorphan is capable of inducing hepatic microsomal enzymes. Studies are needed to determine if this effect also occurs upon chronic administration in humans. These data suggest that the pharmacokinetic characteristic of extensive first-pass metabolism is not necessarily associated with inhibition of drug metabolism.
许多经历广泛首过代谢的药物已被证明会抑制药物的氧化代谢。为了研究这种效应是否与抑制剂的化学结构或药代动力学特征有关,我们测定了右美沙芬(一种与先前研究的药物具有药代动力学相似性但化学结构不同的化合物)对安替比林代谢的影响。在给予安替比林前1小时口服单次剂量的氢溴酸右美沙芬100mg/kg,对该模型底物的药代动力学没有显著影响。以相同剂量每日两次给予右美沙芬,持续3天,并在给予安替比林前1小时额外给药一次,结果安替比林的清除率增加了33%。这些数据表明右美沙芬能够诱导肝微粒体酶。需要进行研究以确定在人体长期给药时是否也会出现这种效应。这些数据表明,广泛首过代谢的药代动力学特征不一定与药物代谢抑制相关。